Rethinking Second-Line Therapy for Overactive Bladder to Improve Patient Access to Treatment Options.
Escobar CM, Falk KN, Mehta S, Hall EF, Menhaji K, Sappenfield EC, Brown OE, Ringel NE, Chang OH, Tellechea LM, Barnes HC, Jeney SES, Bennett AT, Cardenas-Trowers OO.
Escobar CM, et al.
Obstet Gynecol. 2021 Mar 1;137(3):454-460. doi: 10.1097/AOG.0000000000004279.
Obstet Gynecol. 2021.
PMID: 33543891
Review.